STOCK TITAN

Delcath Systems to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Delcath Systems (Nasdaq: DCTH), a company specializing in interventional oncology for liver cancer treatments, has announced its participation in two upcoming investor conferences. The company will participate in the Stephens Biotechnology Virtual Fireside Chats on November 13, 2024, at 9:30 am Eastern Time, which will be held virtually. Additionally, Delcath will attend the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York, NY, where they will conduct one-on-one meetings.

Delcath Systems (Nasdaq: DCTH), un'azienda specializzata nell'oncologia interventistica per i trattamenti del cancro al fegato, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda parteciperà ai Stephens Biotechnology Virtual Fireside Chats il 13 novembre 2024, alle 9:30 ora orientale, che si svolgerà virtualmente. Inoltre, Delcath parteciperà al 15° Annual Craig-Hallum Alpha Select Conference il 19 novembre 2024, a New York, NY, dove condurranno incontri individuali.

Delcath Systems (Nasdaq: DCTH), una empresa especializada en oncología intervencionista para tratamientos de cáncer de hígado, ha anunciado su participación en dos próximas conferencias para inversores. La empresa participará en los Stephens Biotechnology Virtual Fireside Chats el 13 de noviembre de 2024, a las 9:30 a.m. hora del Este, que se llevará a cabo de manera virtual. Además, Delcath asistirá a la 15ª Conferencia Anual Craig-Hallum Alpha Select el 19 de noviembre de 2024, en Nueva York, donde realizarán reuniones uno a uno.

델캐스 시스템즈 (Nasdaq: DCTH)는 간암 치료를 위한 중재 종양학 전문 회사로, 두 개의 투자자 회의에 참여할 것을 발표했습니다. 이 회사는 2024년 11월 13일 동부 시간 오전 9시 30분에 열리는 스티븐스 생명공학 가상 파이어사이드 챗에 참여할 예정입니다. 또한, 델캐스는 2024년 11월 19일 뉴욕에서 열리는 제15회 크레이그-할럼 알파 셀렉트 회의에 참석하여 개별 미팅을 진행할 것입니다.

Delcath Systems (Nasdaq: DCTH), une société spécialisée dans l'oncologie interventionnelle pour le traitement du cancer du foie, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société participera aux Stephens Biotechnology Virtual Fireside Chats le 13 novembre 2024 à 9h30, heure de l'Est, qui se tiendra virtuellement. De plus, Delcath assistera à la 15ème Conférence Annuelle Craig-Hallum Alpha Select le 19 novembre 2024 à New York, NY, où elle mènera des réunions individuelles.

Delcath Systems (Nasdaq: DCTH), ein Unternehmen, das sich auf die interventionelle Onkologie für die Behandlung von Leberkrebs spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird an den Stephens Biotechnology Virtual Fireside Chats am 13. November 2024 um 9:30 Uhr Eastern Time teilnehmen, die virtuell stattfinden werden. Darüber hinaus wird Delcath an der 15. jährlichen Craig-Hallum Alpha Select Conference am 19. November 2024 in New York, NY, teilnehmen, wo sie Einzelgespräche führen werden.

Positive
  • None.
Negative
  • None.

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences:

Stephens Biotechnology Virtual Fireside Chats
Date: Wednesday, November 13, 2024
Fireside Chat Time: 9:30 am Eastern Time
Location: Virtual

15th Annual Craig-Hallum Alpha Select Conference
Date: Tuesday, November 19, 2024
1x1 Meetings
Location: New York, NY

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Investor Relations:

ICR Healthcare

investorrelations@delcath.com

Source: Delcath Systems, Inc.

FAQ

When is Delcath Systems (DCTH) participating in the Stephens Biotechnology Virtual Fireside Chats?

Delcath Systems will participate in the Stephens Biotechnology Virtual Fireside Chats on Wednesday, November 13, 2024, at 9:30 am Eastern Time.

Which investor conferences will Delcath Systems (DCTH) attend in November 2024?

Delcath Systems will attend two conferences: the Stephens Biotechnology Virtual Fireside Chats on November 13 and the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024.

Where will the Craig-Hallum Alpha Select Conference featuring Delcath Systems (DCTH) be held?

The 15th Annual Craig-Hallum Alpha Select Conference will be held in New York, NY on November 19, 2024.

Delcath Systems Inc

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Stock Data

313.66M
29.73M
2.71%
38.13%
4.46%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
QUEENSBURY